科学技术社会化促进了科学交流的出现,科学团体也随之产生.近代中国医学社团引领科学社团创风气之先,而综合科学社团又反过来促进了医学社团的发展.二者在创设初期有关联互动,发展过程中有交流促进,方向定位上有差异区别.以中国科学社为代表的综合科学社团与医学社团,特别是西医社团之间有过密切的学术交流和关系互动.由于对"科学"的不同认知和代表不同的会员群体,在"中医存废之争"中,综合科学社团、西医学社团、中医学社团展现了不同的面相.

目的:探讨由党参和红茶制成的党参红茶对人体淋巴细胞的免疫调节作用.方法:观察不同浓度党参红茶茶包浸出液对淋巴细胞培养的刺激作用.选取180例由脾胃不和、情志劳伤等原因引起气血亏虚的病人,随机分为红茶组、党参组、党参红茶组,各60例,分别给予红茶茶包、党参茶包和党参红茶茶包冲泡饮用.观察3组病人饮用前后气血亏虚证候改善情况.结果:党参搭配红茶感官评价最佳;党参红茶茶包浸出液可提高淋巴细胞增长率和人体免疫力;与红茶组、党参组比较,党参红茶组对气血亏虚症的改善效果更好(P<0.05).结论:党参红茶可调节人体免疫力,提高气血亏虚症的疗效.

西学东渐以来,国人对中医药的自信迭遭质疑,几近废止.中华人民共和国成立后,在党和政府的支持和中医药人的坚守下,中医药发展取得了巨大进步.近年来抗击重大疫情的成效,使得中医药自信逐渐恢复.重塑中医药自信,在人类健康命运共同体构建中发挥重要作用,是新时代中医药人的使命.

Objective To investigate the changes in peripheral blood dendritic cell (DC) subsets in patients with different stages of hepatitis B virus (HBV)-associated disease and related clinical significance.Methods A total of 20 HBV carriers (HBV carrier group),20 chronic hepatitis B (CHB) patients (CHB group),20 hepatitis B cirrhosis patients (cirrhosis group),and 20 primary liver cancer patients (liver cancer group),all of whom had HBV-associated disease and were selected from Department of Hepatology,Longhua Hospital Affiliated to Shanghai University of Traditiond Chinese Medicine,as well as 20 healthy volunteers (normal group),were included in this study flow cytometry was used to measure the changes in DC subsets.Comparison between multiple groups using Druskal-Wallis H test and further comparison using of Wilcoxon Rant test.Results According to the results of myeloid dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs) in patients with different types of HBV infection and normal population,there was a significant difference in the number of mDC between patients with different typers of HBV infection and normal population(x2 =33.629,P ＜0.001),and the cirrhosis group and the liver cancer group had significantly lower numbers of mDCs in peripheral blood than the normal group,CHB group,and HBV carrier group (all P ＜ 0.05).There was a significant difference in the number of pDC between patients with different types of HBV infection and normal population(x2 =13.602,P ＜ 0.009),and the liver cancer group had a significantly lower number of pDCs in peripheral blood than the normal group,CHB group,and HBV carrier group (all P ＜ 0.05).The cirrhosis group had a significantly lower number of pDCs in peripheral blood than the CHB group (P ＜0.05).Conclusion There are significant differences in the expression of DC subsets between patients with different HBV-associated diseases,and the number of DCs may be used as a reference for evaluating disease progression and prognosis.

Objective To evaluate the diagnostic value of anti-mitochondrial antibodies-M2 subtype, anti-gp210, anti-Sp100 by detecting in patients with primary biliary cirrhosis (PBC). Methods Serum samples were detected for AMA-M2, anti-gp210 and anti-Sp100 by immunoblotting assay in 2000 patients with cryptogenic hepatitis, and other 15 healthy individuals were taken as control group. Patients were diagnosed as PBC (129 cases, 6.45%), AIH (205 cases, 10.25%), AIH-PBC overlap syndrome (15 cases, 0.75%), fatty liver (514 cases, 25.70%), drug-induced hepatitis (379 cases, 18.96%), and other unexplained hepatitis (758 cases, 37.90%). Results The positive rates of these three antibodies were 97.67%(126/129), 41.86%(54/129), 27.91%(36/129), respectively. The simultaneous occurrence rate of anti-gp210 and anti-Sp100 was 9.30% (12/129).There were 12 cases with positive anti-gp210 and anti-Sp100 antibody, 3 of whom were diagnosed as PBC through liver puncture. In PBC group, patients with AMA-M2 antibody titer high than 1︰800 accounted for 62.80%(81/129), while the percents of patients with titers ranged from 1︰25 to 1︰100 and from 1︰100 to 1︰200 were 13.95%(18/129) and 30%(12/129), respectively. Conclusions AMA-M2 antibody is still the main marker for PBC diagnosis. The combined detection of AMA-M2 antibody, anti-gp210, anti-Sp100 in PBC have a higher value and play a good supporting role in screening other autoimmune liver diseases.

慢性乙型病毒性肝炎治疗的关键是抗病毒,该文通过近3年来的临床观察和文献研究发现,抗HBV药物干扰素、核苷类药物和中药及其提取物联合治疗慢乙肝取得较满意的疗效,不管是抑制乙肝病毒复制、降低变异率,还是改善肝功能、纤维化和临床症状,联合治疗均优于单一治疗,提示中西医结合治疗有确切的疗效和优势,可能是治疗慢乙肝的首选疗法。

目的:观察中西医结合方法治疗慢性乙型肝炎(慢乙肝)胁痛的临床疗效和对患者生存质量的影响.方法:将72例肝郁脾虚证慢乙肝患者随机分为两组.治疗纽子中西医结合方法治疗4周;对照组予基础药物治疗4周.观察两组治疗前后胁痛情况和生存质量变化.结果:治疗组胁痛临床总有效率88.89%,对照组为58.33%;治疗组对Ⅱ级、Ⅲ级胁痛有较好的疗效,与对照组比较有显著性差异(P<0.05).两组疗效比较有显著性差异(P<0.05),治疗组优于对照组.治疗后治疗组在生理职能、躯体疼痛、活力、情感职能和精神健康方面有显著提高,与对照组比较有显著性差异(P<0.05).结论:中西医结合方法治疗慢性乙型肝炎胁痛可以明显改善患者胁痛病情,提高患者生存质量.

慢性乙型肝炎以抗病毒、免疫调节、抗炎降酶治疗为主,干扰素和核苷类似物广泛应用于临床,但因治疗适应证、药物不良反应和核苷类似物长期应用引起的病毒变异等因素使得治疗受限[1-3].本研究采用苦参素胶囊联合疏肝健脾方治疗低病毒载量慢性乙型肝炎患者,并进行了临床疗效观察,现报告如下.